<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715933</url>
  </required_header>
  <id_info>
    <org_study_id>Ph1 INBRX-109</org_study_id>
    <nct_id>NCT03715933</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas</brief_title>
  <official_title>An Open-Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inhibrx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inhibrx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, open-label, non-randomized, two-part phase 1 trial of INBRX-109,
      which is a recombinant humanized multivalent antibody targeting the human death receptor 5
      (DR5).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events of INBRX-109</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-109</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The MTD and/or RP2D of INBRX-109 will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration time curve (AUC) of INBRX-109</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Area under the serum concentration time curve (AUC) of INBRX-109 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of INBRX-109</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Frequency of ant-drug antibodies (ADA) against INBRX-109 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of INBRX-109</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Maximum observed serum concentration (Cmax) of INBRX-109 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) of INBRX-109</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Trough observed serum concentration (Cmax) of INBRX-109 will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of INBRX-109</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Time to Cmax (Tmax) of INBRX-109 will be determined.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-tumor activity of INBRX-109</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Tumor response will be determined by RECISTv1.1.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Malignant Pleural Mesothelioma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Colorectal Adenocarcinoma</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INBRX-109 will be escalated (3+3 design) in subjects with locally advanced or metastatic solid tumors including sarcomas.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Malignant Pleural Mesothelioma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with malignant pleural mesothelioma will be treated with single-agent INBRX-109 at either the MTD or RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Gastric Adenocarcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with gastric adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Colorectal Adenocarcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with colorectal (CRC) adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INBRX-109 - multivalent DR5 agonist antibody</intervention_name>
    <description>The active ingredient of INBRX-109 is a recombinant, humanized, multivalent antibody that targets the human death receptor 5 (DR5).</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Expansion Colorectal Adenocarcinoma</arm_group_label>
    <arm_group_label>Expansion Gastric Adenocarcinoma</arm_group_label>
    <arm_group_label>Expansion Malignant Pleural Mesothelioma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1 Escalation: Histologically or cytologically-confirmed advanced/metastatic or
             nonresectable solid tumors, including sarcoma, that are refractory or intolerant to
             standard therapy, or for which no standard therapy exists that is likely to confer any
             clinical benefit.

          -  Part 2 Expansion Cohorts: Malignant pleural mesothelioma, gastric adenocarcinoma and
             colorectal adenocarcinoma with locally advanced or metastatic, non-resectable disease,
             that are refractory or intolerant to standard therapy, or for which no standard
             therapy exists that is likely to confer any clinical benefit.

          -  Measurable disease as defined by RECISTv1.1 (or modified RECIST for mesothelioma)
             criteria.

          -  Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 for Part 1
             and ECOG PS of 0, 1 or 2 for Part 2.

        Exclusion Criteria:

          -  Prior treatment with or exposure to DR5 agonists.

          -  Receipt of investigational agents or devices, anticancer therapy and radiotherapy
             (with the exception of palliative localized radiation) within 4 weeks prior to the
             first dose of study drug, and liver-directed therapies (i.e., RFA, TACE/embolization,
             cryotherapy, SBRT) within 12 weeks prior to the first dose of study drug. Exceptions
             per protocol.

          -  Subject has undergone allogeneic hematopoietic stem cell or bone marrow
             transplantation within the last 5 years. Exception: Participants who have had a stem
             cell or bone marrow transplant &gt; 5 years ago are eligible for enrollment, as long as
             there are no symptoms of graft-versus-host disease (GVHD).

          -  Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent
             malignancy whose natural history or treatment does not have the potential to interfere
             with the safety or efficacy assessments of INBRX-109.

          -  Hematologic malignancies.

          -  Known or active primary central nervous system (CNS) tumors, leptomeningeal disease
             and CNS metastases. Exception: Subjects with previously treated, asymptomatic, and
             clinically stable CNS metastases may be allowed study entry if certain criteria apply.

          -  Subjects with chronic liver diseases including but not limited to cirrhosis,
             non-alcoholic fatty liver disease, alcohol-related liver disease, hemochromatosis,
             Wilson's disease, alpha-1 antitrypsin deficiency, hepatic or biliary autoimmune
             disorders (i.e., primary biliary cholangitis, autoimmune hepatitis).

          -  Acute viral or toxic liver disease within 4 weeks prior to the first dose of study
             drug.

          -  Evidence or history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
             infection.

          -  Clinically significant cardiac condition, including myocardial infarction,
             uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart
             disease &lt; 3 months; left ventricular ejection fraction (LVEF) &lt; 50%; New York Heart
             Association (NYHA) Class III or IV congestive heart failure; or uncontrolled
             hypertension. Active, hemodynamically significant pulmonary embolism within 3 months
             prior to enrollment on this trial.

          -  Major surgery within 4 weeks prior to enrollment on this trial.

          -  Systemic infection requiring antibiotics within 2 weeks prior to the first dose of
             study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Wagner, CMO</last_name>
    <role>Study Director</role>
    <affiliation>Inhibrx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Bayer, MgrClinOps</last_name>
    <phone>858-500-7833</phone>
    <email>clinicaltrials@inhibrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, RN</last_name>
      <phone>480-323-1791</phone>
      <email>mailto:clinicaltrials@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shamili Thiagarajan</last_name>
      <phone>626-218-0979</phone>
      <email>sthiagarajan@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>New Patient Services Coordinator</last_name>
      <phone>1-800-826-4673</phone>
      <email>newpatientref@coh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Chao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Chua-Alcala</last_name>
      <phone>310-552-9999</phone>
      <email>vchua@sarcomaoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sant P Chawla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Nguyen</last_name>
      <phone>720-848-4394</phone>
      <email>ana.nguyen@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Lieu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University - Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Scott</last_name>
      <phone>404-778-4083</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Hill</last_name>
      <phone>773-834-1472</phone>
      <email>bhill22@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Buerkley Rose</last_name>
      <phone>773-834-4002</phone>
      <email>brose@bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hedy Kindler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Midwest Michigan, PC</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Robinson</last_name>
      <phone>616-389-1739</phone>
      <email>Katie.Robinson@startmidwest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gita Dangol</last_name>
      <phone>713-792-2913</phone>
      <email>GDangol@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Anna Lui</last_name>
      <phone>713-792-4843</phone>
      <email>ALui@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Vivek Subbiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Gomez</last_name>
      <phone>210-595-5670</phone>
      <email>sgomez@nextsat.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Phase 1 Clinical Trial</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Pleural Mesothelioma</keyword>
  <keyword>Stomach Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Rectal Cancer</keyword>
  <keyword>DR5</keyword>
  <keyword>Gastric Adenocarcinoma</keyword>
  <keyword>Colorectal Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

